Key facts
- This page summarizes Steven DenBaars's Form 4 filing for Palomino Laboratories Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Oct 2025, 16:21.
Steven DenBaars - 29 Sep 2025 Form 4 Insider Report for Palomino Laboratories Inc.
- Reporting relationship
- Director
- Issuer ticker
- PALX on OTC
- Reported as of
- 29 Sep 2025
- Net transaction value
- +$150,000
- SEC form
- 4
- Accepted by SEC
- 09 Oct 2025, 16:21:04 UTC
- Prior SEC filing
- 12 Sep 2025
- Next SEC filing
- 02 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven Denbaars
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steven DenBaars filed Form 4 for Palomino Laboratories Inc. on 09 Oct 2025.
Change
- Previous filing in this sequence was filed on 12 Sep 2025.
- Current net transaction value: +$150,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001700533
Primary reporting owner
Denbaars Steven
- Relationship
- Director
- Address
- 313 BRYANT COURT, PALO ALTO,
- Signature
- /s/ Steven Denbaars
- Signature date
- 09 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
No ticker
transaction
Common Stock
Other
- Transaction value
- Shares
- +1,625,000
- Change %
- +1300%
- Price
- Shares after
- 1,750,000
- Date
- 29 Sep 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
transaction
Derivative
Warrants
Sale
- Transaction value
- $150,000
- Shares
- +125,000
- Change %
- Price
- $1.20
- Shares after
- 125,000
- Date
- 29 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125,000
- Exercise price
- $1.50
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. DenBaars, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, during which, Mr. DenBaars converted his SAFEs into 125,000 Units at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in warrant agreement).